Search Within

Peter Maslak

  1. "Population Sciences Research Program"
Formats
  1. Journal Article (6)
  2. Meeting Abstract (3)
Groups
  1. Adult Leukemia (9)
  2. Center for Hematologic Malignancies (9)
  3. Department of Medicine (9)
  4. Hematologic Malignancies, Division of (9)
  5. Population Sciences Research Program (9)
  6. Biostatistics Service (8)

More Groups

People
  1. Katherine Panageas (8)
  2. David Scheinberg (5)
  3. Joseph Jurcic (5)
  4. Nicole Lamanna (5)
  5. Mark Weiss (4)
  6. Alison Gencarelli (3)

More People

Years
  1. 2013 (3)
  2. 2011 (1)
  3. 2009 (1)
  4. 2008 (1)
  5. 2006 (1)
  6. 2005 (2)
Publications
  1. Journal of Clinical Oncology (4)
  2. Blood (1)
  3. Cancer (1)
  4. Clinical Cancer Research (1)
  5. Leukemia Research (1)
  6. Nature Genetics (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. American Association for Cancer Research (1)
  3. American Society of Hematology (1)
  4. Elsevier Ltd (1)
  5. Nature Publishing Group (1)
  6. Wiley Blackwell (1)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia
    Journal Article

    Shah, S.; Schrader, K. A.; Waanders, E.; Timms, A. E.; Vijai, J.; Miething, C.; Wechsler, J.; Yang, J.; Hayes, J.; Klein, R. J.; more...
    Nature Genetics (2013)

    Fulltext@MSK | Save
  • Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?: Results from a prospective randomized trial
    Journal Article

    Lamanna, N.; Heffner, L. T.; Kalaycio, M.; Schiller, G.; Coutre, S.; Moore, J.; Seiter, K.; Maslak, P.; Panageas, K.; Golde, D.; more...
    Cancer (2013)

    Fulltext@MSK | Save
  • Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis
    Journal Article

    Diab, A.; Zickl, L.; Abdel-Wahab, O.; Jhanwar, S.; Gulam, M. A.; Panageas, K. S.; Patel, J. P.; Jurcic, J.; Maslak, P.; Paietta, E.; more...
    Leukemia Research (2013)

    Fulltext@MSK | Save
  • Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM)
    Meeting Abstract

    Krug, L. M.; Tsao, A. S.; Kass, S.; Rusch, V. W.; Travis, W. D.; Panageas, K.; Adusumili, P. S.; Kris, M. G.; Maslak, P. G.; Scheinberg, D. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
    Journal Article

    Lamanna, N.; Jurcic, J. G.; Noy, A.; Maslak, P.; Gencarelli, A. N.; Panageas, K. S.; Heaney, M. L.; Brentjens, R. J.; Golde, D. W.; Scheinberg, D. A.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (Romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes
    Journal Article

    Klimek, V. M.; Fircanis, S.; Maslak, P.; Guernah, I.; Baum, M.; Wu, N.; Panageas, K.; Wright, J. J.; Pandolfi, P. P.; Nimer, S. D.
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J. G.; Heaney, M.; Brentjens, R.; Zelenetz, A. D.; Horgan, D.; Gencarelli, A.; Panageas, K. S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL
    Meeting Abstract

    Weiss, M. A.; Heffner, L.; Lamanna, N.; Kalaycio, M.; Schiller, G.; Coutre, S.; Maslak, P.; Jurcic, J.; Panageas, K.; Scheinberg, D. A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia
    Meeting Abstract

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Heaney, M. L.; Brentjens, R.; Jurcic, J.; Biederman, E.; Gencarelli, A. N.; Panageas, K. S.; Scheinberg, D. A.; more...
    Blood (2005)

    Fulltext@MSK | Save